NCT02394119View on ClinicalTrials.gov

Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

May 31, 2019

Conditions
Nephrotic Syndrome
Interventions
DRUG

Ofatumumab

1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline

DRUG

Rituximab

375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.

Trial Locations (1)

16147

IRCCS Istituto Giannina Gaslini, Genoa

All Listed Sponsors
lead

Istituto Giannina Gaslini

OTHER

NCT02394119 - Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome | Biotech Hunter | Biotech Hunter